** Shares of Akero Therapeutics AKRO.O up 1.8% premarket to $52.39 after co raises more equity than targeted
** Co late Tues said sold ~7.3 mln shares, including ~2 mln pre-funded warrants, at $48 for approx $350 mln gross proceeds
** On Mon, AKRO shares surged 97.5% to $51.71 after co said its lead drug, efruxifermin, showed it can help reverse scarring in patients with type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** Shares on Tues edged down 0.5% and closed at $51.47 as co marketed $300 mln offering
** Co has ~69.8 mln shares outstanding for $3.6 bln market cap, per LSEG
** JP Morgan, Morgan Stanley and Jefferies are jt bookrunners for the offering
** Separately, 89Bio ETNB.O raised $250 mln of equity to fund its MASH drug candidate
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。